Compare Johnson & Johnson (JNJ) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Under Armour Inc Class A — how do they compare? Johnson & Johnson trades at $260.7 (market cap $626.09B), while Under Armour Inc Class A trades at $5.28 (market cap $2.26B). The key difference: Johnson & Johnson is far larger — about 277× Under Armour Inc Class A's market cap, and Johnson & Johnson pays a 2.06% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| JNJ | UAA | |
|---|---|---|
Market Cap | $626.09B | $2.26B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $8.14 |
52-Week Low | $172.78 | $4.17 |
Enterprise Value | $654.37B | $3.24B |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Under Armour (UAA) is trading at $5.245, down 10.49% today, reflecting ongoing challenges with revenue declines and negative profitability. The stock shows bearish technical signals with oversold RSI readings, while fundamentals reveal a net loss of -$201.27M in 2025 and negative cash flow trends. Recent Q1 2027 earnings beat expectations but revealed weaker revenue and cautious guidance, with management maintaining profitability outlook despite sales headwinds.
The outlook remains challenging with declining revenues and negative margins, though current valuation metrics appear reasonable. Key risks include weak North American demand and competitive pressures, while potential catalysts include new product collaborations and cost management. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
